Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings.
The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the main vessel and side branch. At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis.
Tanabe
Kengo
K
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Hoye
Angela
A
Lemos
Pedro A
PA
Aoki
Jiro
J
Arampatzis
Chourmouzios A
CA
Saia
Francesco
F
Lee
Chi-hang
CH
Degertekin
Muzzafer
M
Hofma
Sjoerd H
SH
Sianos
Georgios
G
McFadden
Eugene
E
Smits
Pieter C
PC
van der Giessen
Willem J
WJ
de Feyter
Pim
P
van Domburg
Ron T
RT
Serruys
Patrick W
PW
D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000401:mortality* / Q000473:pathology; D005260:Female; D005431:Florida; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus